MK-431 (Merck).

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

MK-431 (Merck). / Deacon, Carolyn F.

In: Current Opinion in Investigational Drugs, Vol. 6, No. 4, 2005, p. 419-26.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Deacon, CF 2005, 'MK-431 (Merck).', Current Opinion in Investigational Drugs, vol. 6, no. 4, pp. 419-26.

APA

Deacon, C. F. (2005). MK-431 (Merck). Current Opinion in Investigational Drugs, 6(4), 419-26.

Vancouver

Deacon CF. MK-431 (Merck). Current Opinion in Investigational Drugs. 2005;6(4):419-26.

Author

Deacon, Carolyn F. / MK-431 (Merck). In: Current Opinion in Investigational Drugs. 2005 ; Vol. 6, No. 4. pp. 419-26.

Bibtex

@article{bd3c5e90ab4b11ddb5e9000ea68e967b,
title = "MK-431 (Merck).",
abstract = "Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.",
author = "Deacon, {Carolyn F}",
note = "Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Clinical Trials as Topic; Drug Industry; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Triazoles",
year = "2005",
language = "English",
volume = "6",
pages = "419--26",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - MK-431 (Merck).

AU - Deacon, Carolyn F

N1 - Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Clinical Trials as Topic; Drug Industry; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Triazoles

PY - 2005

Y1 - 2005

N2 - Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.

AB - Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.

M3 - Journal article

C2 - 15898349

VL - 6

SP - 419

EP - 426

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -

ID: 8417240